Semaglutide vs Tirzepatide
Single-agonist GLP-1 vs dual-agonist GLP-1+GIP — head-to-head dose, weight-loss, side-effect and cost comparison.
TL;DR
Tirzepatide produces ~20.9% body weight loss at 72 weeks (SURMOUNT-1) vs ~14.9% for semaglutide (STEP-1) at the highest dose. Tirzepatide adds GIP agonism on top of GLP-1, which appears to drive both stronger appetite suppression and better fat-mass-preferred loss. Side-effect profiles are similar (GI-dominant); semaglutide has a longer real-world safety track and broader insurance coverage.
Side-by-side
How they work — side-by-side
Semaglutide is a long-acting GLP-1 receptor agonist. GLP-1 is an incretin hormone released by the gut after eating; activating its receptor slows gastric emptying, increases satiety signaling in the hypothalamus, and amplifies glucose-dependent insulin secretion from pancreatic beta cells. Net effect: lower appetite, reduced calorie intake, improved post-meal glycemia.
Tirzepatide hits the same GLP-1 receptor but also activates the GIP (glucose-dependent insulinotropic polypeptide) receptor. GIP is a second incretin that — when paired with GLP-1 — appears to amplify the satiety and energy-expenditure effects beyond what either hormone produces alone. Animal and human data suggest dual-agonism preferentially mobilizes fat mass over lean mass.
The clinical consequence: tirzepatide head-to-head against semaglutide (SURPASS-2) produced both greater HbA1c reduction and greater weight loss at every dose comparison. SURMOUNT-1 (obesity, non-diabetic) showed mean 20.9% weight loss at 15 mg vs STEP-1's 14.9% for semaglutide 2.4 mg.
When to choose which
Semaglutide
Choose Semaglutide if
Semaglutide is the better fit when track record, oral-availability, or insurance coverage matter more than peak efficacy.
- Insurance covers Wegovy/Ozempic but not Zepbound/Mounjaro
- You want the oral form (Rybelsus) instead of weekly injections
- Cardiovascular risk reduction matters (FDA-approved indication)
- You're sensitive to side effects and want the longer real-world safety dataset
- You don't need >15% body weight loss
Tirzepatide
Choose Tirzepatide if
Tirzepatide is the better fit when peak weight loss, glycemic control, or fat-mass-preferred body recomposition is the goal.
- Weight-loss target >15% of body weight
- Semaglutide plateaued before goal was reached
- HbA1c is well above target despite max-dose GLP-1 monotherapy
- Sleep apnea is a stated indication (Zepbound is FDA-approved for OSA in obesity)
- You prioritize fat-mass loss with lean-mass preservation
Redundant — don't stack
Do not stack semaglutide and tirzepatide. Both saturate the GLP-1 receptor; running them together gives you double GI side effects with no additional weight-loss benefit. The correct move when semaglutide plateaus is to switch to tirzepatide — not add it. Allow a 2-week washout before transitioning to avoid stacked half-lives.
Safety + side-effect contrast
Both compounds share the same GI-dominant side-effect profile (nausea, vomiting, diarrhea, constipation), the same pancreatitis and gallbladder-disease signals, and the same boxed warning for medullary thyroid carcinoma based on rodent studies. The differences are at the margins.
- Tirzepatide GI side effects are dose-proportional and tend to be slightly higher in incidence at top doses, but the absolute difference is small (≤5 percentage points).
- Semaglutide has a longer real-world safety dataset — 8+ years of post-marketing data vs ~2-3 years for tirzepatide.
- Tirzepatide users report slightly more constipation and slightly less nausea than semaglutide users.
- Both require dose titration starting at the lowest level to manage GI tolerance.
- Neither is safe in pregnancy. Both require a 2-month washout before conception.
Frequently asked
Is tirzepatide better than semaglutide?
For weight loss and glycemic control, tirzepatide produces better outcomes at the highest dose levels — about 20.9% body weight loss at 72 weeks vs 14.9% for semaglutide. That said, 'better' depends on your goal: semaglutide has a longer real-world safety track, broader insurance coverage, oral availability (Rybelsus), and FDA-approved cardiovascular indications.
Can I switch from semaglutide to tirzepatide?
Yes, this is a common transition when semaglutide plateaus. Standard practice: complete your current semaglutide week, wait one week, then start tirzepatide at 2.5 mg weekly. Some protocols start at 5 mg if you were already at 1.7–2.4 mg semaglutide. Discuss with your prescribing clinician.
Why is tirzepatide more effective?
Tirzepatide activates both the GLP-1 and the GIP receptor. GLP-1 alone slows gastric emptying and increases satiety. Adding GIP agonism appears to amplify satiety signaling and shift the energy-balance equation in favor of fat-mass loss over lean-mass loss. The dual-agonist mechanism is the key distinction.
Do semaglutide and tirzepatide have the same side effects?
Largely yes — both share GI-dominant side effects (nausea, vomiting, diarrhea, constipation) with similar incidence. Tirzepatide users report slightly more constipation and slightly less nausea. Both carry the same boxed warning for medullary thyroid carcinoma and the same gallbladder/pancreatitis signals.
Which is cheaper?
Cash prices are nearly identical — both run roughly $1,000–1,350 per month in the US without insurance. Semaglutide (Wegovy/Ozempic) has broader insurance coverage because it's been on the market longer. Tirzepatide (Zepbound/Mounjaro) coverage is growing but still less consistent.
Cited research
Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med, 2022.
Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med, 2021.
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med, 2021.
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med, 2016.
Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med, 2024.
Need a personalized semaglutide vs tirzepatide call?
The Coach takes your bloodwork, goals, and tolerance into account and outputs a cited protocol card — saved as a branded PDF you can take to your doctor.
Ask the Coach